GSK plc Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹1.0L Cr
- GSK expects another year of profitable growth in 2026, confirmed in their guidance. - GSK expects another year of profitable growth, with guidance confirmed during the Q1 2026 results call.
From GSK plc's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹51.24
Market Cap
₹1.0L Cr
P/E Ratio
13.4
Revenue Rank
Margin Rank
How does GSK plc rank in Pharmaceuticals?
Compare GSK plc against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →GSK expects another year of profitable growth in 2026, confirmed in their guidance.
- →Specialty Medicines sales grew 14% in Q1 and continue to drive overall growth.
- →Vaccines, notably Shingrix, contributed significantly with a 20% sales increase in Q1; however, tougher comparators expected later this year in Europe and Japan.
- →New product launches like Nucala COPD, Exdensur, and Blenrep show strong momentum and growth potential.
- →Pipeline acceleration and BD activities focus on high-potential assets, including COPD, oncology ADCs, and Efimosfermin in MASH.
- →HIV portfolio growth continues with a 10% sales increase in Q1 alongside advancements in long-acting regimens.
- →Jemperli is on track to reach the £2 billion revenue potential in oncology with upcoming trial results expected to further support growth.
- →Inventory stocking effects (e.g., Shingrix) may moderate but underlying demand remains stable or improving in key markets like China and the U.S.
📈 Profitability & Margins
Rank 3- →GSK expects another year of profitable growth, with guidance confirmed during the Q1 2026 results call.
- →Core operating profit grew 10% in Q1, reflecting strong sales and improved product mix.
- →Earnings per share (EPS) increased by 9% in Q1, supported by higher operating profit and share buybacks.
- →Cash generation was strong at GBP 1.4 billion, supporting capital allocation priorities.
- →Operating profit growth is expected to be predominantly weighted towards the second half of the year, factoring in productivity benefits and prior year comparators.
- →Continued investment in R&D and pipeline acceleration aims to drive future top-line growth and commercial success.
- →The company is committed to accelerating late-stage pipeline assets and lifecycle management to enhance growth prospects and shareholder value.
🏗️ Capital Expenditure Plans
Yes- →Investments in business development (BD) primarily included a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics.
- →In Q2, an expected outflow of $950 million for the acquisition of 35Pharma, whose lead asset HS235 is in Phase I development for pulmonary hypertension.
- →Portfolio optimization actions such as the divestment of the Rockville manufacturing site and the out-licensing of linerixibat contributed to capital generation.
- →Strategic acquisitions in Q1 included ozureprubart (for food allergies) and HS235 (pulmonary hypertension), both aiming to be best-in-class assets.
- →Planning to reinvest cash income from strategic actions and strong cash generation into pipeline acceleration and growth initiatives.
- →Share buyback continued on track and shareholder returns totaled over GBP 0.9 billion.
- →Overall, capital deployment focused on disciplined BD, accelerating late-stage pipeline, and productivity improvements.
💰 Fundraising & Capital Structure
No information- →No explicit mention of new fundraising through debt or equity in the provided excerpts.
- →Company is focused on strong cash generation and capital allocation priorities with net debt at 1.4x EBITDA.
- →Recent investments include a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics.
- →Share buyback program is ongoing and on track for completion at half year.
- →Upcoming outflow of $950 million expected for acquisition of 35Pharma in Q2.
- →Portfolio optimization actions (special dividend, site divestments, out-licensing) are planned to positively impact net debt by $1.2 billion in H1.
- →No mention of issuing new equity or additional debt for fundraising within reported periods.
📋 Order Book & Pipeline
No information- →U.S. Shingrix inventory stocking is around 45%, up 3.5 percentage points versus the same time last year, within the typical annual increase range of 2-4 percentage points.
- →Wholesaler stocking in Q1 2026 was 0.6 million doses, steady compared to 0.5 million at the end of last year and 0.4 million during the same time last year.
- →Retail inventory increased to 2.4 million doses compared to 1.7 million at the same time last year, partly due to the launch of the prefilled syringe (PFS).
- →China demand is improving with an increase in doses administered; however, sales numbers do not yet reflect this due to stock being drawn down from GSK’s inventory.
- →Stocking and inventory build reflect a balance of supply readiness and underlying patient demand, particularly focused on the comorbid population.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
Frequently Asked Questions
What were GSK plc Q2 FY26 results?
- GSK expects another year of profitable growth in 2026, confirmed in their guidance. - GSK expects another year of profitable growth, with guidance confirmed during the Q1 2026 results call.
What is GSK plc share price analysis?
GSK plc currently shows a below-average growth signal. The stock trades at a P/E of 13.4 with a market cap of $104,500. Investors should review the full earnings analysis for detailed insights.
Is GSK plc planning capital expenditure?
- Investments in business development (BD) primarily included a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics.
Keep GSK plc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.